Solventum

SOLV

Market cap $12.9B

SOLV's Q4 earnings and revenues beat estimates, driven by organic growth across MedSurg, Dental and HIS, despite margins declined.

Solventum Corporation (SOLV) Q4 2025 Earnings Call Transcript

The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Solventum (SOLV) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.41 per share a year ago.

Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.

Reported sales decreased 3.7%; organic sales increased 3.5% Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn.

Besides Wall Street's top-and-bottom-line estimates for Solventum (SOLV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

SOLV readies Q4 results amid solid momentum, tariff headwinds, and M&A focus as investors watch margins and growth trends closely.

ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close.

Here is how Solventum (SOLV) and Cronos Group (CRON) have performed compared to their sector so far this year.